基于网络药理学研究策略解析痛泻要方治疗溃疡性结肠炎的分子作用机制

被引：20

作者：

王武斌

于国华

史渊源

机构：

[1] 北京中医药大学生命科学学院

来源：

现代中药研究与实践 | 2020年 / 34卷 / 01期

关键词：

痛泻要方; 溃疡性结肠炎; 网络药理学; 作用机制;

D O I：

10.13728/j.1673-6427.2020.01.008

中图分类号：

R285 [中药药理学];

学科分类号：

100806 [中药药理学];

摘要：

目的运用网络药理学研究策略对痛泻要方治疗溃疡性结肠炎(ulcerative colitis,UC)的作用机制进行预测分析。方法利用BATMAN-TCM在线分析工具与DrugBank和OMIM数据库构建"成分-靶标-通路-疾病"网络及进行通路富集分析,阐释痛泻要方治疗UC的分子作用机制。结果筛选共得到72个痛泻要方活性成分,195个成分候选靶标与12条关键生物学通路,主要集中在炎症-免疫反应、神经调节作用、生长发育等生物学过程,其中JAK-STAT通路参与了多个生物学过程。经分析,Thymol、Lauric Acid、N-Methyltyramine等成分可能是作用于UC的关键活性成分。结论运用网络药理学研究策略对痛泻要方治疗UC的生物学过程进行靶标预测和网络构建,阐释了痛泻要方作用于UC的潜在分子机制,为痛泻要方治疗UC的活性成分药物筛选提供理论依据。

引用

页码：28 / 34

页数：7

共 26 条

[1]

基于系统生物学的肝癌分子机制及护肝片治作用研究 [D].

李丕栋 .

西北农林科技大学,

2016

[2]

Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis [J].

Parisinos, Constantinos A. ;

Serghiou, Stylianos ;

Katsoulis, Michail ;

George, Marc Jonathan ;

Patel, Riyaz S. ;

Hemingway, Harry ;

Hingorani, Aroon D. .

GASTROENTEROLOGY, 2018, 155 (02) :303-+

[3]

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-only Crohn’s Disease in Treatment-naïve Pediatric Patients.[J].Michael J. Rosen;Rebekah Karns;Jefferson E. Vallance;Ramona Bezold;Amanda Waddell;Margaret H. Collins;Yael Haberman;Phillip Minar;Robert N. Baldassano;Jeffrey S. Hyams;Susan S. Baker;Richard Kellermayer;Joshua D. Noe;Anne M. Griffiths;Joel R. Rosh;Wallace V. Crandall;Melvin B. Heyman;David R. Mack;Michael D. Kappelman;James Mark

[4]

Ulcerative colitis [J].

Ungaro, Ryan ;

Mehandru, Saurabh ;

Allen, Patrick B. ;

Peyrin-Biroulet, Laurent ;

Colombel, Jean-Frederic .

LANCET, 2017, 389 (10080) :1756-1770

[5]

Macrophage-Restricted Interleukin-10 Receptor Deficiency, but Not IL-10 Deficiency, Causes Severe Spontaneous Colitis [J].

Zigmond, Ehud ;

Bernshtein, Biana ;

Friedlander, Gilgi ;

Walker, Catherine R. ;

Yona, Simon ;

Kim, Ki-Wook ;

Brenner, Ori ;

Krauthgamer, Rita ;

Varol, Chen ;

Mueller, Werner ;

Jung, Steffen .

IMMUNITY, 2014, 40 (05) :720-733

[6]

The overlap between IBS and IBD – what is it and what does it mean?.[J].Stanisic;Quigley.Expert Review of Gastroenterology & Hepatology.2014, 2

[7]

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review [J].

Molodecky, Natalie A. ;

Soon, Ing Shian ;

Rabi, Doreen M. ;

Ghali, William A. ;

Ferris, Mollie ;

Chernoff, Greg ;

Benchimol, Eric I. ;

Panaccione, Remo ;

Ghosh, Subrata ;

Barkema, Herman W. ;

Kaplan, Gilaad G. .

GASTROENTEROLOGY, 2012, 142 (01) :46-54

[8]

Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.[J].RivkahGonsky;Richard L.Deem;Carol J.Landers;Carrie A.Derkowski;DrorBerel;Dermot P.B.McGovern;Stephan R.Targan.Inflamm Bowel Dis.2010, 1

[9]

Infliximab therapy decreases the levels of TNF-&agr; and IFN-&ggr; mRNA in colonic mucosa of ulcerative colitis.[J].Trine Olsen;Guanglin Cui;Rasmus Goll;Anne Husebekk;Jon Florholmen.Scandinavian Journal of Gastroenterology.2009, 6

[10]

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review.[J].Daniel Tracey;Lars Klareskog;Eric H. Sasso;Jochen G. Salfeld;Paul P. Tak.Pharmacology and Therapeutics.2007, 2

← 1 2 3 →